Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT07026240 for Gastric Cancer is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One study matched filter criteria
Card View
Post-operative Monitoring of Gastric Cancer 258 Non-Invasive Biomarker-Driven
Clinical Trial NCT07026240 is an observational study for Gastric Cancer that is recruiting. It started on February 18, 2024 with plans to enroll 258 participants. Led by Suzhou Huhu Health & Technology Inc., it is expected to complete by January 7, 2026. The latest data from ClinicalTrials.gov was last updated on June 18, 2025.
Brief Summary
This study is to determine the performance of non-invasive new multi-target biomarkers in the post-operative monitoring of gastric cancer.
Detailed Description
This study aims to develop and validate a new non-invasive detection method for postoperative monitoring of gastric cancer in the blood. Blood will also be collected at various time points post-operatively. We will determine whether these new biomarkers can be used as prognostic biomarkers to predict tumor recurrence and metastasis. We will also determine whether these new biomarkers detect tumor recurrence and metas...Show More
Official Title
Post-operative Monitoring of Gastric Cancer Using Circulating DNA in Blood Samples
Conditions
Gastric CancerOther Study IDs
- 2311285-6（1）
NCT ID Number
Start Date (Actual)
2024-02-18
Last Update Posted
2025-06-18
Completion Date (Estimated)
2026-01-07
Enrollment (Estimated)
258
Study Type
Observational
Status
Recruiting
Arms / Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
malignant group Subjects diagnosed with gastric cancer. | DNA test a new non-invasive detection method for postoperative monitoring of gastric cancer in the blood |
Primary Outcome Measures
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
The performance of the new biomarkers in the post-operative monitoring of gastric cancer | Number of Participants With Tumor Recurrence Detected by the New System vs. Imaging and Serum Markers (CA19-9, CEA, CA72-4). | 2 years |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Metastasis Detection Time: New vs. Conventional Methods | Time to Detection of Metastasis (Days) by the New System Compared to Conventional Methods. | 2 years |
Participation Assistant
Eligibility Criteria
Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
- Subject age over 18.
- Subject has stomach discomfort, and seek medical attention at the Gastric Surgery Department of our center.
- Subject has or will have gastroscopy and/or pathological examination results at this center.
- Subject must be able to fully understand the informed consent form and be able to personally sign it.
- Subject has serious heart, liver, kidney dysfunction, or mental illness.
- Subject diagnosed previously with any kind of malignant tumor.
- Subject is known to be infected with HIV or other related diseases (considering interference from the use of immune drugs).
- Subject is receiving targeted drugs, immunosuppressants, immunomodulators, and biological therapies.
- Researchers believe that subject is not suitable for enrollment.
- Subject can not supply sufficient sample to complete this experiment.
Suzhou Huhu Health & Technology Inc.Fudan University829 active studies to exploreStudy Central Contact
Contact: Dazhi Xu, MD., PhD,, +86 13862036541, [email protected]
1 Study Locations in 1 Countries
Shanghai Municipality
Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality, 200032, China
Dazhi Xu, MD., PhD, Contact, +8615862461212, [email protected]
Recruiting